MedPath

Dietary Intervention to Reduce Metabolic Endotoxemia

Not Applicable
Completed
Conditions
Dietary Habits
Clinical Trial
Intestinal Microbiota
Endotoxemia
Obesity
Interventions
Behavioral: CONV-D
Behavioral: AIA-D
Registration Number
NCT05776329
Lead Sponsor
Centro de Investigación en Alimentación y Desarrollo A.C.
Brief Summary

The goal of this randomized clinical trial is to compare an antiinflammatory and environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and including nutrients related to antiinflammatory responses with an active control diet based on general healthy diet recommendations (CONV-D) in adults from 18 to 50 years of age with obesity (body mass index ≥30 kg/m2). The main questions it aims to answer are:

* If the intervention with AIA-D will cause a significant decrease at the end of the intervention (six weeks) in lipopolysaccharide-binding protein (LBP) compared to CONV-D.

* If intervention with AIA-D will cause a significant increase at the end of the intervention (six weeks) in the relative abundance of two specific bacteria genera (AM and FP) when compared to CONV-D.

Participants will:

* Sign the informed consent.

* Provide two peripheral blood samples (taken by our trained professionals).

* Provide two samples of feces.

* Allow anthropometric (body weight, height, hip and waist circumferences) blood pressure measurements on two occasions.

* Respond to 24 h dietary recall on two occasions.

* Attend the 1-hour group sessions requested (three for AIA-D and one for CONV-D).

* Follow the dietary recommendations provided.

* Be willing to participate in social media groups to receive information and follow up during the six weeks of the intervention.

Researchers will compare an antiinflammatory and environmentally friendly strategy (AIA-D) with an active control diet (CONV-D) based on general healthy diet recommendations to see if AIA-D decreases metabolic endotoxemia measured through LBP serum levels and increase the relative abundance of AM and FP, compared to CONV-D.

Detailed Description

This randomized clinical trial proposes to evaluate an environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and including nutrients related to anti-inflammatory responses that can decrease metabolic endotoxemia and promote FP and AM growth associated with anti-inflammatory effects and good intestinal health compared to an active control diet (CONV-D) general healthy diet recommendations.

Primary hypothesis: The intervention with a low-inflammatory and environmentally friendly dietary strategy aimed at adults diagnosed with obesity (body mass index ≥30 kg/m2) will cause a significant decrease at the end of the intervention (six weeks) in the levels of lipopolysaccharide-binding protein (metabolic endotoxemia), and significantly increase the relative abundance of AM and FP, when compared to general healthy diet recommendations.

Secondary hypotheses: The intervention with a low-inflammatory and environmentally friendly dietary strategy aimed at adults diagnosed with obesity (body mass index ≥30 kg/m2) will cause a significant increase at the end of the intervention (six weeks) in the relative abundance of Prevotella, when compared to general healthy diet recommendations.

The intervention with a low-inflammatory and environmentally friendly dietary strategy aimed at adults diagnosed with obesity (body mass index ≥30 kg/m2) will cause a significant decrease at the end of the intervention (six weeks) of body weight, percentage of body fat, body mass index, circumferences of waist and hip when compared to general healthy diet recommendations.

The intervention with a low-inflammatory and environmentally friendly dietary strategy aimed at adults diagnosed with obesity (body mass index ≥30 kg/m2) will improve blood pressure more than the general healthy diet recommendations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  • Obesity according to body mass index: ≥ 30 kg/m2
  • Willingness to participate and sign the consent form.
  • Willingness to follow the dietary recommendations of the protocol.
  • Have access to the internet and an electronic device.
Exclusion Criteria
  • Clinically diagnosed with hyperglycemia, hypertension, cardiovascular disease, renal disease, hepatic disease, immunosuppression, or another metabolic disease.
  • Being under a dietary restriction regimen or pharmacological treatment to lose weight.
  • Consuming dietary supplements for at least six months (vitamins, fatty acids, probiotics, prebiotics).
  • Being under treatment with antibiotics or anti-inflammatory drugs in the last three months.
  • Having bariatric surgery.
  • Being pregnant or lactating.
  • Present gastrointestinal disease
  • Present Coronavirus disease (COVID-19) symptoms
  • Develop diseases that affect body weight
  • Becoming pregnant
  • Withdrawal of informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
General healthy diet recommendations (CONV-D).CONV-DThe active comparator CONV-D is based on the general healthy diet recommendations
Low-inflammatory and environmentally friendly dietary strategy (AIA-D)AIA-DThe environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and includes nutrients related to anti-inflammatory responses
Primary Outcome Measures
NameTimeMethod
Change in relative abundance of AMBaseline to six weeks

According to the manufacturer's instructions, total DNA will be extracted from fecal samples and quantified by a spectrophotometer, where the ratio of 1.8-2.0 (260/280) is acceptable. DNA samples will be stored at -80°C until analysis. AM will be amplified from DNA extracted from fecal samples by quantitative polymerase chain reaction (qPCR). A specific set of primers will be used. The relative expression of the gen (relative abundance) will be calculated. The 16S ribosomal RNA (16S) (V4) normalizing gen will be used for analysis.

Change in Lipopolysaccharide-binding protein (LBP).Baseline to six weeks

Peripheral blood samples will be taken before and after the intervention, centrifuged for serum extraction, and stored at -80°C until analysis. ELISA kits were used to quantify LBP.

Change in relative abundance of FPBaseline to six weeks

According to the manufacturer's instructions, total DNA will be extracted from fecal samples and quantified by a spectrophotometer, where the ratio of 1.8-2.0 (260/280) is acceptable. DNA samples will be stored at -80°C until analysis. FP will be amplified from DNA extracted from fecal samples by quantitative polymerase chain reaction (qPCR). A specific set of primers will be used. The relative expression of the gen (relative abundance) will be calculated. The 16S ribosomal RNA (16S) (V4) normalizing gen will be used for analysis.

Secondary Outcome Measures
NameTimeMethod
Change in abundance of PrevotellaBaseline to six weeks

According to the manufacturer's instructions, total DNA will be extracted from fecal samples and quantified by a spectrophotometer, where the ratio of 1.8-2.0 (260/280) is acceptable. DNA samples will be stored at -80°C until analysis. Prevotella will be amplified from DNA extracted from fecal samples by quantitative polymerase chain reaction (qPCR). A specific set of primers will be used. The relative expression of the gen (relative abundance) will be calculated. The 16S ribosomal RNA (16S) (V4) normalizing gen will be used for analysis.

Change in waist circumferenceBaseline to six weeks

The waist circumference will be measured using a flexible anthropometric tape (200 cm) at the level of the umbilicus

Change in percentage of body fatBaseline to six weeks

An electrical bioimpedance analysis device will measure body fat.

Change in hip circumferenceBaseline to six weeks

The hip circumference will be measured using a flexible anthropometric tape (200 cm) at the widest circumference of the gluteus.

Change in body weightBaseline to six weeks

Body weight will be measured with minimal clothing using a digital electronic scale (capacity of 0 to 150 ± 0.05 kg).

Change in the dietary inflammatory index.Baseline to six weeks

The DII and energy-adjusted-DII (E-DII) will be calculated from the dietary data collected using 24-h dietary recall for each participant. E-DII scores were calculated using the density approach wherein all nutrients were converted to 1000 kcal consumption.

Change in body mass indexBaseline to six weeks

The body mass index will be calculated by dividing the weight (kg) by the square of height (m). Height will be measured using a stadiometer (rank 0.70-2.05 m) while barefoot participants were standing with their heads in the Frankfurt plane

Change in waist-to-hip ratioBaseline to six weeks

The waist-to-hip ratio will be calculated by dividing waist circumference (cm) by hip circumference (cm).

Change in blood pressureBaseline to six weeks

Systolic and diastolic blood pressure will be measured by a digital device.

RetentionBaseline to six weeks

Percentage of participants that finished the intervention

Trial Locations

Locations (2)

Centro de Investigación en Alimentación y Desarrollo

🇲🇽

Hermosillo, Sonora, Mexico

Universidad Vizcaya de las Américas

🇲🇽

Hermosillo, Sonora, Mexico

© Copyright 2025. All Rights Reserved by MedPath